GRAIL Reports Strong Q3 2025 Financial Progress
U.S. Galleri revenue increased 28% year-over-year to $32.6 million.
Galleri tests sold surged 39% per year, exceeding 45,000.
FDA PMA submission for Galleri is anticipated in early 2026.
Current cash position exceeds $850 million, bolstered by a recent private placement.
In its latest business update, GRAIL, Inc. (NASDAQ: GRAL), a health company focused on the early detection of cancer, outlined robust financial results for the third quarter of 2025. The total revenue soared 26% year-over-year to $36.2 million, with Galleri generating $32.8 million, reflecting a growth of 29%. Notably, the U.S. Galleri revenue alone reached $32.6 million, marking a significant 28% increase over the same period last year. Despite these encouraging figures, the company reported a net loss of $89 million.
"We are thrilled with Galleri's ongoing acceptance, marked by a 39% growth in test volumes this quarter," said Bob Ragusa, GRAIL's CEO. "We're focusing on increasing awareness of our test among primary care providers and patients, and recent findings from our PATHFINDER 2 study bolster our case for Galleri." Bob highlighted the company's strategic moves to expand into Asian markets via a collaboration with Samsung and its introduction in Canada.
Key Financial Highlights
For the quarter ending September 30, 2025, GRAIL provided the following financial comparisons with the prior year:
- Total Revenue: $36.2 million, a boost of $7.5 million (26%).
- Net Loss: $89 million, an improvement of $36.7 million (29%).
- Gross Loss: $13.7 million, a reduction of $8.5 million (38%).
- Adjusted Gross Profit: $20 million, increasing by $8.2 million (69%).
- Adjusted EBITDA: $(71.7 million), improving by $36.5 million (34%).
- Cash Position: Cash and equivalents reached $547.1 million as of September 30, 2025.
Recent Business Highlights
Recent advancements include:
- Positive results from the PATHFINDER 2 study reinforce the effectiveness of Galleri in multi-cancer early detection.
- Key outcomes presented at the European Society of Medical Oncology (ESMO) Congress demonstrated significant enhancements when Galleri was combined with standard screenings.
- Over 75% of cancers detected by Galleri currently lack standard screening options, with many diagnosed at earlier stages.
- GRAIL has partnered with Medcan to offer Galleri tests in its clinics and through Manulife's Vitality program.
- A strategic collaboration with Samsung was announced to roll out Galleri in select Asian regions, with an intended investment of $110 million by Samsung.
- The company completed a private placement bringing in approximately $325 million, strengthening its cash foundation into 2030.
Looking Forward
As GRAIL continues to push towards a better future, its focus remains on enhancing early cancer detection technologies. Galleri presents a groundbreaking approach offering vital insights into cancer types that currently lack efficient screening methods. With anticipated developments ahead, including regulatory approvals and market expansions, GRAIL remains committed to revolutionizing cancer care.
About GRAIL
GRAIL, Inc. is on a mission to detect cancer early when treatment options are more effective. The company leverages advanced technologies such as next-generation sequencing and machine learning to identify multiple cancer types at earlier stages. Based in Menlo Park, California, GRAIL's efforts target screening and precision oncology through innovative diagnostic solutions.
Frequently Asked Questions
What is the main focus of GRAIL?
GRAIL specializes in the early detection of cancer using advanced technology to identify multiple cancer types through blood tests.
How much did GRAIL earn in Q3 2025?
GRAIL reported total revenue of $36.2 million for Q3 2025, with significant contributions from its Galleri tests.
What trends are evident in Galleri tests sold?
Galleri tests sold grew by 39% year-over-year, reflecting a rising acceptance of GRAIL's technology.
What are GRAIL's future plans?
GRAIL plans to complete an FDA submission for its Galleri test in early 2026 and expand its presence into new markets.
How does GRAIL contribute to cancer management?
GRAIL develops tests that empower healthcare providers to detect cancers earlier, improving treatment outcomes, and reducing mortality rates.
